Abstract：
Cisplatin-based chemotherapy is frequently employed as the primary therapeutic approach for advanced lung cancer. Nevertheless, a significant proportion of patients may develop resistance to cisplatin, leading to diminished efficacy of chemotherapy. Through analysis of Gene Expression Omnibus databases, TSPAN6 has been identified as a key factor in conferring resistance to cisplatin, attributed to its activation of the NF-κB signaling pathway. Knockdown of TSPAN6 using siRNA resulted in decreased expression levels of NF-κB in A549 cells. This indicates that TSPAN6 may have dual effects on lung cancer cisplatin resistance and could serve as a promising therapeutic target for individuals with cisplatin resistance.
摘要：
基于顺铂的化疗经常被用作晚期肺癌的主要治疗方法。然而，相当比例的患者可能对顺铂产生耐药性，导致化疗疗效下降。通过分析基因表达综合数据库，TSPAN6已被确定为赋予顺铂耐药性的关键因素，归因于其对NF-κB信号通路的激活。使用siRNA敲低TSPAN6导致A549细胞中NF-κB的表达水平降低。这表明TSPAN6可能对肺癌顺铂耐药性具有双重作用，并且可以作为具有顺铂耐药性的个体的有希望的治疗靶标。
